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Abstract —Evidence-based approach for the use and selection 
of nutraceuticals are presented as well as the need and challenges 
to creating a method for the standardization of these products. A 
systematic review was completed to analyze the impact of 
evidence-based and standardization of nutraceuticals. Evidence-
based approach for nutraceuticals allow for the evaluation of these 
products. This process involves utilizing current and best evidence 
to provide individualized care for patients. Current Good 
Manufacturing Practices (cGMP) are regulations enforced by the 
FDA to ensure that drug manufacturing processes meet basic 
standards. Under these practices, design, monitoring, and control 
of manufacturing processes are regulated. These practices can 
track and provide tools to prevent contamination of products 
available to consumers. Using evidence-based approach for 
nutraceutical can provide healthcare providers and consumers 
with evidence that is patient specific, for a given intervention and 
desired outcome. The global market for nutraceuticals is growing 
and all manufacturers should comply with cGMP to ensure safe, 
quality products for consumers. The goal is to have all 
nutraceutical manufacturers worldwide embrace cGMP in order 
to provide consumers with safe, effective and high quality 
products. 
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Dr. Lockwood defines a nutraceutical as “the term used to 
describe a medicinal or nutritional component that includes a 
food, plant, or naturally occurring material, which may have 
been purified or concentrated, and that is used for the 
improvement of health, by preventing or treating a disease1.” 
This includes anything from dietary supplements used for 
weight loss to herbal supplements and vitamins. Evidence-
based medicine (EBM) is the use of the best, current available 
scientific research to make informed decisions about patient 
care. EBM integrates clinical expertise with evidence-based 
research and patient specific factors. The purpose of this study 
was to present evidence-based approaches for the use and 
selection of nutraceuticals as well as the need and challenges to 
creating a method for the standardization of these products. A 
systematic literature review was completed to analyze the 
impact of evidence-based approach to nutraceuticals and 
standardization of the regulatory process of nutraceuticals. 
 
Dr. Hasnain-Wynia Romana states that EBM is the use of 
evidence that can allow clinicians to draw upon the objective 
experience of researchers working through scientific standards,  
 
 
improve efficiency of providers, decrease the use of ineffective 
clinical practices, aid in informing patients and clinicians by 
offering collectively agreed upon and publicly available 
information about treatment options and lastly provide a 
scientific basis for the construction of health care policy2. 
 
Izzo, Raffaele et al investigated whether addition of 
nutraceuticals to lifestyle management including diet 
counseling improved lipid profile and reduced cardiovascular 
risk and prevalence of metabolic syndrome3. 
 
One thousand, three hundred and eighty, 18 to 80 year-old 
non-diabetic participants with dyslipidemia, with or without 
metabolic syndrome not requiring pharmacological therapy 
were assigned to a specific diet; after 2 weeks, 690 patients 
were also given a nutraceutical combination over another 8 
weeks3. 
 
Patients receiving nutraceuticals were older and more 
dyslipidemic than the placebo group, with no difference in 
other cardiovascular risk factors and prevalence of metabolic 
syndrome. After 8 weeks, high-density lipoprotein (HDL) 
cholesterol was increased and diastolic blood pressure, waist 
girth, triglycerides, total and non-HDL cholesterol were 
significantly reduced in the nutraceutical group than in the 
placebo group. However, systolic blood pressure and fasting 
glucose did not change2. Prevalence of metabolic syndrome 
was also significantly lower in the nutraceutical group (36.1%) 
than in the placebo group (48.1%, P < 0.05) and a reduction in 
the Framingham Risk Score, which calculates ten-year risk of 
coronary heart disease, of 73.3 vs. 52%, respectively (P < 
0.0001)3. 
 
Their study concluded that in their large clinical sample of 
patients with moderate cardiovascular risk, combination of 
nutraceutical with dietary counseling reduced central obesity, 
improved lipid profile, diastolic blood pressure and 
Framingham Risk Score, and decreased prevalence of 
metabolic syndrome3. 
 
Khera et al measured the effect of niacin on HDL 
functionality but concluded niacin failed to improve clinical 
outcomes when adjunct to standard LDL cholesterol targeted 
therapy, such as statins, despite a significant increase in HDL-
C levels4. 
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 Carol P. Wilson et al investigated whether or not riboflavin 
would be effective in lowering blood pressure when added to 
conventional antihypertensive therapies in patients with the 
methylenetetrahydrofolate reductase (MTHFR) 677TT 
genotype but without apparent cardiovascular disease. 
Although this was a small trial with only 91 participants, they 
found that blood pressure control rates increased from 32% to 
60% with the addition of riboflavin to treatment regimens in at 
risk patients with this genotype5.  
 
Welma Stonehouse et al designed a study to determine 
whether adding a docosahexaeonic (DHA) supplement would 
improve cognitive functioning in healthy adults. They also 
studied whether sex or the apolipoprotein E (APOE) genotype 
would affect the response to the DHA supplementation. This 
randomized control trial had a total of 176 participants ranging 
from 18 to 45 years old. Participants had to be nonsmokers and 
have a low dietary intake of DHA. They were randomly 
assigned to receive either the placebo or the DHA supplement. 
The trial concluded that DHA supplementation did improve 
memory and the reaction times of memory as well. In addition, 
sex affected the outcome. The researchers found that various 
memory functions were improved in the two different sexes. 
They suggest further studies must be completed in order to fully 
understand the effects6.  
 
The articles outlined above were reviewed in order to 
research the theory that nutraceuticals have a need for more 
evidence-based use. While not all of the articles had conclusive 
or even favorable outcomes, they do support the need for more 
research and therefore more educated usage of nutraceuticals. 
With more trials comes more knowledge, and with more 
knowledge comes more appropriate use.  Another possible 
outcome that may arise with additional trials would be the 
ability to enforce more standardization laws on industries that 
manufacture such products. 
 
Current Good Manufacturing Practices (cGMP) are 
regulations enforced by the FDA. The FDA ensures that drug 
manufacturing processes meet basic objectives under the 
cGMP. Under these practice designs, monitoring and control of 
manufacturing processes are observed and regulated. Facilities 
where production takes place along with materials and 
equipment are inspected to assure quality standards.  
 
Unlike manufactured pharmaceutical drugs, nutraceuticals 
are not widely regulated by the FDA.  In fact, the FDA is not 
required to demand registration or grant approval from dietary 
manufacturing companies prior to marketing a product7. This is 
due to the Dietary Supplement Health and Education Act 
(DSHEA) of 1994, which states it is the sole responsibility of 
the developers and manufacturers to ensure a safe and 
beneficial product before marketing.  This limits the FDA from 
intervening during dietary product manufacturing and states 
that a manufacturing company is required to submit official 
documentation of ingredients used only when marketing a 
product with “new dietary ingredients”8.  
 
The FDA's responsibility is to oversee product-labeling, 
claims made by the manufacturer regarding the product, and 
package inserts. The Federal Trade Commission (FTC) on the 
other hand specifically regulates the advertisement of dietary 
supplements 8. DSHEA regulates health claims of dietary 
supplements, but manufacturers and marketers are not required 
to prove the safety or efficacy of their products. While DSHEA 
strives to improve the safety and labeling of dietary 
supplements, dietary supplement manufacturers do not conduct 
clinical studies like pharmaceutical manufacturers do and thus 
are held to a different standards9. 
 
According to DSHEA, the dietary supplement can state that 
these products can offer nutritional support to individuals with 
nutrient-deficient diseases, but the companies are expected to 
write that the FDA has not evaluated their statements. Further, 
they must state that this product is not intended to diagnose, 
treat, cure, or prevent any disease. The FDA expects that 
nutraceuticals are manufactured under cGMPs and gradually 
the FDA is moving toward more rigorous regulations for 
nutraceuticals. 
 
In the global consumer market nutraceuticals are an ever-
growing industry and until recently, the manufacturing and 
quality control of these products have been largely unregulated. 
Requirements for expiration dating, supporting data and testing 
methods validity are unclear. These confusing regulatory 
requirements result in inconsistency and inefficient regulation 
therefore bringing forth the challenge of stability testing of 
nutraceuticals10. 
  
Using an evidence-based approach for nutraceuticals can 
provide healthcare providers and consumers with evidence 
regarding the selection and use of these products. Selection and 
use of nutraceuticals can be specific for each patient’s given 
intervention and desired outcome to decrease healthcare costs 
and aid in disease prevention and treatment. There is a dire need 
for further research to aid healthcare providers and consumers 
in making more evidence-based decisions regarding 
nutraceutical use. 
 
There is also a critical need for nutraceutical industries to 
embrace current good manufacturing practices to ensure that 
consumers have safe, efficacious products. Clinical studies 
giving rise to evidence based medicine would yield more 
accurate labeling and not only be beneficial for the industry to 
have statements of worth on the product but also solidify the 
trust of the consumers. Consumers can be assured the product 
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 is following cGMPs and that reliable, scientific methods were 
used to support the products.  The global market for 
nutraceuticals is ever growing and all nutraceutical 
manufacturers should comply with and embrace cGMP to 
ensure safe, quality products for consumers. The goal is to have 
all nutraceutical manufacturers worldwide follow cGMP in 
order to provide consumers with safe, effective and high quality 
products that are imperative in promoting a healthy lifestyle. 
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